Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China

Real-world analysis of the efficacy and safety of lorlatinib in ALK-positive non-small cell lung cancer patients in China

IntroductionLorlatinib, a third-generation ALK inhibitor, has demonstrated strong efficacy in treating advanced ALK-positive NSCLC, though real-world data, particularly from China, are limited. This study evaluates the real-world efficacy and safety of lorlatinib in Chinese patients with advanced AL...

Full description

Saved in:
Bibliographic Details
Main Authors: Guangming Tian, Jun Nie, Ling Dai, Weiheng Hu, Jie Zhang, Di Wu, Xiangjuan Ma, Xiaoling Chen, Sen Han, Jindi Han, Ziran Zhang, Jieran Long, Xinliang Zhao, Jian Fang
Format: Article
Language:English
Published: Frontiers Media S.A. 2025-05-01
Series:Frontiers in Oncology
Subjects:
NSCLC
lorlatinib
real-world
efficacy
safety
China
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2025.1577607/full
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items